Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Chief People & Culture Off | September 28, 2026 | September 30, 2026 |
| Sonendo, Inc.SONX · Entity 9738 | Director | June 16, 2023 | June 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,478 |
Reported balance
After 2026-09-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-28 · Sale · Disposed 2,565 · Balance 123,478 F1: On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Sonendo, Inc.
Report date June 16, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,998 |
Reported balance
After 2023-06-16 transaction · row 1
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 25,316 · Balance 59,998 F1: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2033-06-15 | Direct | 32,520 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Grant · Acquired 32,520 · Balance 32,520 F2: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date.
F2: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
3D SYSTEMS CORP
Report date September 03, 2020 · Filed September 08, 2020
Section 16 reporting ended · disclosed 2020-09-08. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Sep 30, 2026 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,565 | $86.15 | $220,974.75 |
DisclosureSEC source: 0001093557-26-000181 · wk-form4_1790799305.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief People & Culture Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,478 F1 · shares: On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,565 | $88.37 | $226,669.05 |
DisclosureSEC source: 0001093557-26-000161 · wk-form4_1787950632.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief People & Culture Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,043 F1 · shares: On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| August 22, 2026 Filed Aug 25, 2026 20:14 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 1,451 | $92.34 | $133,985.34 |
DisclosureSEC source: 0001093557-26-000156 · wk-form4_1787688867.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief People & Culture Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,608 F1 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:39 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 1,451 | $71.90 | $104,326.90 |
DisclosureSEC source: 0001093557-26-000096 · wk-form4_1779914337.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief People & Culture Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,059 F1 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 17,199 | $68.10 | $1,171,251.90 |
DisclosureSEC source: 0001093557-26-000047 · wk-form4_1773172900.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,510 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 39,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000047 · wk-form4_1773172900.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,709 F1 · shares: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 2,656 | $73.36 | $194,844.16 |
DisclosureSEC source: 0001093557-26-000012 · wk-form4_1770068797.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,690 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 7,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000012 · wk-form4_1770068797.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,346 F1 · shares: Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 8, 2023, resulting from achievement of performance conditions under the PSUs. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:06 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,466 | $80.00 | $117,280.00 |
DisclosureSEC source: 0001093557-25-000251 · wk-form4_1757362012.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,223 F1 · shares: On February 20, 2025, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 20:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,466 | $88.99 | $130,459.34 |
DisclosureSEC source: 0001093557-25-000234 · wk-form4_1753820279.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,689 F1 · shares: On February 20, 2025, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 22:47 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,466 | $85.06 | $124,697.96 |
DisclosureSEC source: 0001093557-25-000222 · wk-form4_1751323654.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,155 F1 · shares: On February 20, 2025, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:51 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,184 | $85.11 | $526,318.38 |
DisclosureSEC source: 0001093557-25-000199 · wk-form4_1748465469.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,621 F1 · shares: On February 20, 2025, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.75 to $85.445. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 11,176 | $70.38 | $786,568.00 |
DisclosureSEC source: 0001093557-25-000078 · wk-form4_1741987499.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,805 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| March 08, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 22,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000064 · wk-form4_1741735035.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,981 F2 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F3 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| March 08, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 29,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000064 · wk-form4_1741735035.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,183 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| January 29, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,093 | $86.91 | $181,911.21 |
DisclosureSEC source: 0001093557-25-000017 · wk-form4_1738280650.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,261 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 43,283 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000017 · wk-form4_1738280650.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,354 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F2 · balance_after: Included in this number are 43,283 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 424 | $76.87 | $32,592.88 |
DisclosureSEC source: 0001093557-24-000192 · wk-form4_1734470143.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,768 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 43,283 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,259 | $74.73 | $318,275.07 |
DisclosureSEC source: 0001093557-24-000184 · wk-form4_1732310139.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,192 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 44,115 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 832 of which were granted on December 15, 2021 and shall vest through December 15, 2024. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 23:05 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 426 | $69.15 | $29,457.90 |
DisclosureSEC source: 0001093557-24-000169 · wk-form4_1726095915.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,451 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 52,323 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 832 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 22:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 427 | $115.05 | $49,126.95 |
DisclosureSEC source: 0001093557-24-000128 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,877 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 53,159 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,668 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 25, 2024 Filed Mar 26, 2024 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,137 | $140.00 | $579,180.00 |
DisclosureSEC source: 0001093557-24-000058 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,304 F1 · shares: On December 15, 2022, Ms. Stern adopted a 10b5-1 Plan which was amended on December 12, 2023. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 75 | $132.71 | $9,952.96 |
DisclosureSEC source: 0001093557-24-000053 · edgardoc.xml · nonDerivative · entry 6 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,441 F3 · shares: On December 15, 2022, Ms. Stern adopted a 10b5-1 Plan which was amended on December 12, 2023. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $132.62 to $133.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 302 | $131.51 | $39,714.60 |
DisclosureSEC source: 0001093557-24-000053 · edgardoc.xml · nonDerivative · entry 5 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,516 F3 · shares: On December 15, 2022, Ms. Stern adopted a 10b5-1 Plan which was amended on December 12, 2023. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $131.36 to $131.80. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,297 | $133.43 | $439,918.71 |
DisclosureSEC source: 0001093557-24-000053 · edgardoc.xml · nonDerivative · entry 4 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,818 F3 · shares: On December 15, 2022, Ms. Stern adopted a 10b5-1 Plan which was amended on December 12, 2023. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $133.00 to $133.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,577 | $132.46 | $341,358.95 |
DisclosureSEC source: 0001093557-24-000053 · edgardoc.xml · nonDerivative · entry 3 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,115 F3 · shares: On December 15, 2022, Ms. Stern adopted a 10b5-1 Plan which was amended on December 12, 2023. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $131.98 to $132.86. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,437 | $131.50 | $320,461.60 |
DisclosureSEC source: 0001093557-24-000053 · edgardoc.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,692 F3 · shares: On December 15, 2022, Ms. Stern adopted a 10b5-1 Plan which was amended on December 12, 2023. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $130.89 to $131.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 11,633 | $134.41 | $1,563,599.67 |
DisclosureSEC source: 0001093557-24-000053 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,129 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:32 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 21,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000039 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,762 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 53,995 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,504 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 23:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,902 | $123.63 | $358,788.19 |
DisclosureSEC source: 0001093557-24-000014 · edgardoc.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,051 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,953 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,340 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 23:56 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 7,620 | $0.00 | $7.62 |
DisclosureSEC source: 0001093557-24-000014 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,953 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F2 · balance_after: Included in this number are 54,953 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,340 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:36 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,675 | $121.85 | $204,097.75 |
DisclosureSEC source: 0001093557-23-000254 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,333 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,953 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,340 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 23:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 392 | $117.66 | $46,122.72 |
DisclosureSEC source: 0001093557-23-000240 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,008 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 58,297 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 20:51 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,176 | $110.00 | $129,360.00 |
DisclosureSEC source: 0001093557-23-000232 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,400 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 58,297 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| November 19, 2023 Filed Nov 21, 2023 00:27 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,106 | $104.06 | $427,283.50 |
DisclosureSEC source: 0001093557-23-000230 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,576 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 58,297 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 19:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 392 | $110.71 | $43,398.32 |
DisclosureSEC source: 0001093557-23-000176 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,682 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| July 10, 2023 Filed Jul 10, 2023 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 392 | $128.05 | $50,195.60 |
DisclosureSEC source: 0001093557-23-000163 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,074 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 01:03 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantStock Option (Right to Buy) · Derivative | 32,520 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001562180-23-005392 · primarydocument.xml · derivative · entry 2 Stern Sadie · CIK 0001797971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,520 Underlying: Common Stock · 32,520 shares Expires 2033-06-15 F2 · derivative.exercise_date: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 01:03 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 25,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005392 · primarydocument.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,998 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 393 | $121.31 | $47,674.83 |
DisclosureSEC source: 0001093557-23-000152 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,466 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| May 09, 2023 Filed May 9, 2023 22:24 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 393 | $120.19 | $47,234.67 |
DisclosureSEC source: 0001093557-23-000122 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,859 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 20:02 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 393 | $112.35 | $44,153.55 |
DisclosureSEC source: 0001093557-23-000102 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,252 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 20:03 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 393 | $111.86 | $43,960.98 |
DisclosureSEC source: 0001093557-23-000087 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,645 F1 · shares: On December 14, 2022, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:53 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,565 | $111.40 | $397,137.44 |
DisclosureSEC source: 0001093557-23-000084 · edgardoc.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,038 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:53 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,550 | $111.40 | $284,067.45 |
DisclosureSEC source: 0001093557-23-000084 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,603 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 21,769 | $0.00 | $21.77 |
DisclosureSEC source: 0001093557-23-000050 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,153 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 66,505 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,844 | $112.62 | $432,910.51 |
DisclosureSEC source: 0001093557-22-000177 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,384 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 59,312 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 15,024 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 12:47 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantStock Options (Right to buy) · Derivative | 49,586 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001562180-22-005428 · primarydocument.xml · derivative · entry 2 Stern Sadie · CIK 0001797971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,586 Underlying: Common Stock · 49,586 shares Expires 2032-06-28 F2 · derivative.exercise_date: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 12:47 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 34,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005428 · primarydocument.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,682 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:30 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 701 | $406.06 | $284,645.75 |
DisclosureSEC source: 0001093557-22-000056 · edgardoc.xml · nonDerivative · entry 2 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,057 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 16,880 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.